tiprankstipranks
Advertisement
Advertisement

TBPH Stock Latest News

Theravance Biopharma downgraded to Neutral from Buy at H.C. Wainwright
The FlyTheravance Biopharma downgraded to Neutral from Buy at H.C. Wainwright
14d ago
TBPH
Zymeworks price target raised to $37 from $35 at Citi
PremiumThe Fly
Zymeworks price target raised to $37 from $35 at Citi
21d ago
TBPH
ZYME
Theravance Biopharma downgraded to Neutral from Buy at BTIG
PremiumThe Fly
Theravance Biopharma downgraded to Neutral from Buy at BTIG
22d ago
TBPH
Morning Movers: Comcast surges after announcing spinoff of NBCUniversal
PremiumThe Fly
Morning Movers: Comcast surges after announcing spinoff of NBCUniversal
22d ago
VZ
BTI
Theravance Biopharma downgraded to Hold from Buy at JonesResearch
PremiumThe Fly
Theravance Biopharma downgraded to Hold from Buy at JonesResearch
22d ago
TBPH
Theravance Biopharma to be Acquired by Zymeworks
PremiumCompany AnnouncementsTheravance Biopharma to be Acquired by Zymeworks
22d ago
8K
TBPH
M&A News: Biotech Group Zymeworks Buys Lung Disease-Fighting Peer Theravance for $1B
Premium
Market News
M&A News: Biotech Group Zymeworks Buys Lung Disease-Fighting Peer Theravance for $1B
22d ago
TBPH
ZYME
Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash
Premium
The Fly
Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash
22d ago
TBPH
ZYME
Zymeworks to acquire Theravance Biopharma for $17.00 per share, or $929M
PremiumThe Fly
Zymeworks to acquire Theravance Biopharma for $17.00 per share, or $929M
22d ago
TBPH
ZYME
Zymeworks to acquire Theravance Biopharma for $17.00 per share
PremiumThe Fly
Zymeworks to acquire Theravance Biopharma for $17.00 per share
22d ago
TBPH
ZYME
Theravance Biopharma announces leadership changes amid restructuring
PremiumCompany Announcements
Theravance Biopharma announces leadership changes amid restructuring
27d ago
8K
TBPH
Theravance Biopharma Shareholders Back Directors and Governance Plans
PremiumCompany Announcements
Theravance Biopharma Shareholders Back Directors and Governance Plans
1M ago
8K
TBPH
Theravance Biopharma: Solid 1Q26 Execution, Cost Cuts, and YUPELRI Momentum Drive Buy Rating and Price Target Increase to $19
PremiumRatingsTheravance Biopharma: Solid 1Q26 Execution, Cost Cuts, and YUPELRI Momentum Drive Buy Rating and Price Target Increase to $19
2M ago
TBPH
Theravance: Hold Rating Reiterated as Restructuring Progress and Cash Flow Visibility Support Unchanged $15 Price Target
Premium
Ratings
Theravance: Hold Rating Reiterated as Restructuring Progress and Cash Flow Visibility Support Unchanged $15 Price Target
2M ago
TBPH
Theravance Biopharma reports Q1 EPS (10c) vs. (17c) last year
Premium
The Fly
Theravance Biopharma reports Q1 EPS (10c) vs. (17c) last year
2M ago
TBPH
TBPH Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
TBPH Upcoming Earnings Report: What to Expect?
3M ago
TBPH
Theravance Biopharma price target raised to $17 from $14 at B. Riley
PremiumThe Fly
Theravance Biopharma price target raised to $17 from $14 at B. Riley
3M ago
MNKD
TBPH
Theravance Secures Long-Term YUPELRI Patent Litigation Settlement
PremiumCompany Announcements
Theravance Secures Long-Term YUPELRI Patent Litigation Settlement
4M ago
8K
TBPH
Theravance Biopharma price target raised to $15 from $13 at TD Cowen
PremiumThe Fly
Theravance Biopharma price target raised to $15 from $13 at TD Cowen
4M ago
TBPH
Theravance Biopharma: Post‑CYPRESS Restructuring Leaves Limited Upside and Justifies Neutral Stance
PremiumRatingsTheravance Biopharma: Post‑CYPRESS Restructuring Leaves Limited Upside and Justifies Neutral Stance
4M ago
TBPH
Theravance Biopharma reports Q4 EPS $1.15, consensus $1.10
Premium
The Fly
Theravance Biopharma reports Q4 EPS $1.15, consensus $1.10
4M ago
TBPH
Theravance Biopharma options imply 3.2% move in share price post-earnings
Premium
The Fly
Theravance Biopharma options imply 3.2% move in share price post-earnings
5M ago
TBPH

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >